UPDATE - Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease

Stock Information for Gain Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Gain Therapeutics Inc.

Gain Therapeutics to Participate at The Citizens Life Sciences Conference
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.